| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | tumor antigen CTAA16.88 |
| Clinical data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Technetium (99mTc) votumumab (trade name HumaSPECT) is a human monoclonal antibody labelled with the radionuclide technetium-99m.[1][2] It was developed for the detection of colorectal tumors, but has never been marketed.[3]
The target of votumumab is CTAA16.88, a complex of cytokeratin polypeptides in the molecular weight range of 35 to 43 kDa, which is expressed in colorectal tumors.[4]
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (1). 1999.
- ↑ Hendriks BS, Gaddy DF (2017). "Radiolabeled Antibody-Based Imaging in Clinical Oncology". In Olivier Jr KJ, Hurvitz SA (eds.). Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer. Hoboken, New Jersey: John Wiley & Sons. p. 441. ISBN 978-1-119-06084-0.
- ↑ "Public Statement on HumaSPECT" (PDF). European Medicines Agency (EMA_. 23 February 2004. Archived from the original (PDF) on 2007-06-10.
Non-renewal of the marketing authorisation in the European Union
- ↑ "Summary of Product Characteristics for HumaSPECT" (PDF). European Medicines Agency (EMA).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.